Entrada Therapeutics, Inc. (TRDA)
NASDAQ: TRDA · Real-Time Price · USD
5.87
-0.31 (-5.02%)
At close: Oct 17, 2025, 4:00 PM EDT
5.87
0.00 (0.00%)
After-hours: Oct 17, 2025, 4:31 PM EDT

Company Description

Entrada Therapeutics, Inc., is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible.

The Company’s Endosomal Escape Vehicle (EEV™)-therapeutics are designed to enable the efficient intracellular delivery of a wide range of therapeutics into a variety of organs and tissues, resulting in an improved therapeutic index.

Through this proprietary, versatile and modular approach, Entrada is advancing a robust development portfolio of RNA- and protein-based programmes for the potential treatment of neuromuscular and ocular diseases, among others.

The company was formerly known as CycloPorters, Inc., and changed its name to Entrada Therapeutics, Inc., in October 2017.

Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.

Entrada Therapeutics, Inc.
Entrada Therapeutics logo
CountryUnited States
Founded2016
IPO DateOct 29, 2021
IndustryBiotechnology
SectorHealthcare
Employees183
CEODipal Doshi

Contact Details

Address:
One Design Center Place, Suite 17- 500
Boston, Massachusetts 02210
United States
Phone857 520 9158
Websiteentradatx.com

Stock Details

Ticker SymbolTRDA
ExchangeNASDAQ
Stock TypeCommon Stock
Fiscal YearJanuary - December
Reporting CurrencyUSD
IPO Price$20.00
CIK Code0001689375
CUSIP Number29384C108
ISIN NumberUS29384C1080
Employer ID81-3983399
SIC Code2834

Key Executives

NamePosition
Dipal DoshiChief Executive Officer and Director
Nathan J. DowdenPresident and Chief Operating Officer
Dr. Natarajan Sethuraman Ph.D.President of Research and Development
Kory James Wentworth CPAChief Financial Officer and Treasurer
Dr. Jared Cohen J.D., Ph.D.General Counsel
Kerry Robert M.S.Senior Vice President of People
Karla MacDonaldChief Corporate Affairs Officer
Kevin Healy Ph.D.Senior Vice President of Regulatory Affairs
Sandeep BasnetHead of Information Technology

Latest SEC Filings

DateTypeTitle
Aug 14, 2025SCHEDULE 13G/AFiling
Aug 14, 2025SCHEDULE 13G/AFiling
Aug 6, 202510-QQuarterly Report
Aug 6, 20258-KCurrent Report
Jul 9, 2025144Filing
Jul 9, 2025144Filing
Jul 1, 2025144Filing
Jul 1, 2025144Filing
Jun 30, 2025144Filing
Jun 30, 2025144Filing